Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. News about ALZN often centers on the progress of its two main product candidates, AL001 and ALZN002, as well as financing transactions and corporate actions disclosed through press releases and SEC filings.
Investors following ALZN news can expect detailed updates on the company’s Phase II "Lithium in Brain" clinical program for AL001. These reports describe head-to-head studies of AL001 versus marketed lithium carbonate products, including enrollment milestones, dosing of the first patient, and completion of the clinical portion of trials in healthy subjects. Company announcements also highlight collaborations with Massachusetts General Hospital, Tesla Dynamic Coils BV and QMENTA to support high-resolution brain imaging and AI-driven analysis of lithium distribution.
Alzamend Neuro’s news flow also includes information on its ALZN002 active immunotherapy program targeting beta-amyloid in Alzheimer’s, operational developments in clinical trial management, and capital-raising activities such as private placements of preferred stock and related warrant issuances. Corporate updates, including reverse stock split decisions and governance matters reported on Form 8-K, are frequently summarized in press releases.
This ALZN news page aggregates these updates so readers can review clinical milestones, financing events and regulatory disclosures in one place. For those tracking the development of AL001 and ALZN002, or monitoring Alzamend Neuro’s Nasdaq-listed common stock, the news feed offers a consolidated view of the company’s publicly reported activities and announcements.
Alzamend Neuro, Inc. (Nasdaq: ALZN) reported a net loss of $5.4 million, or $0.06 per share, for the quarter ending January 31, 2023, compared to a loss of $2.6 million, or $0.03 per share, year-over-year. Cash on hand was $7.4 million, with a note receivable of $14.8 million expected by December 2023. The company is initiating a Phase I/IIA clinical trial for ALZN002, targeting mild to moderate Alzheimer’s dementia, expected to begin by March 2023. Topline data for AL001's Phase IIA trial is anticipated in June 2023, which focuses on dementia related to Alzheimer’s. R&D expenses rose to $2.9 million amid increased clinical activities.
Alzamend Neuro, a biopharmaceutical company focused on innovative treatments for Alzheimer's disease, bipolar disorder, and PTSD, will present at the Sequire Biotechnology Conference on February 2, 2023 at 10:30 a.m. ET. CEO Stephan Jackman is expected to discuss recent milestones, including the completion of a Phase I study for AL001 and progress on ALZN002. The biotechnology sector is projected to grow to over $727 billion by 2025, supporting the increasing interest in public biotech investments. Attendees can register to view the presentation HERE.
Alzamend Neuro, Inc. (NASDAQ: ALZN) announced a partnership with Biorasi to conduct a Phase I/IIA clinical trial evaluating the safety, tolerability, and efficacy of ALZN002, an immunotherapy for mild-to-moderate Alzheimer's dementia. The trial will involve 20-30 subjects, with initial results expected to inform a larger Phase IIB trial within three months. ALZN002, a patient-specific therapy, utilizes autologous dendritic cells to target amyloid-beta proteins. The company aims to initiate the trial by March 2023, marking a significant step in Alzheimer’s treatment research.
Alzamend Neuro, Inc. (NASDAQ: ALZN) is advancing its Phase IIA clinical trial of AL001, a treatment for Alzheimer’s-related dementia, with topline data expected in Q2 2023. The trial, initiated in May 2022, aims to assess safety and tolerability under multiple ascending doses. Additionally, Alzamend is collaborating with the University of Miami for the Phase I/IIA trial of ALZN002, an immunotherapeutic vaccine designed to combat Alzheimer’s. These developments may expedite further research and provide pivotal insight into effective treatments for Alzheimer’s and related conditions.
BitNile Holdings (NILE) reported strong financial results for Q3 2022, with total revenue of $49.8 million, up from a negative $30.8 million in Q3 2021. Key highlights include:
- Revenue from cryptocurrency mining reached $3.9 million.
- Revenue from The Singing Machine Company (MICS) was $17.1 million.
- Net loss reduced to $7.5 million from $42.9 million.
- Total assets stood at $610.9 million.
The company is optimistic about future growth, targeting a revenue run rate of $200 million.
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, announced that CEO Stephan Jackman will be featured on the Fox Business Network on November 16, 2022. Jackman will share insights on their recent progress, including the initiation of a Phase IIA study for AL001 and the FDA's approval to begin a Phase I/IIA trial for ALZN002, an immunotherapeutic vaccine. Alzamend is focused on developing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
BitNile Holdings announced that Alzamend Neuro received FDA approval for a Phase I/IIA trial of ALZN002, an autologous dendritic cell-based immunotherapy vaccine for Alzheimer's treatment.
ALZN002 could be the first of its kind tested in humans, utilizing the patient's own cells to potentially improve safety and efficacy. The trial aims to evaluate safety and optimal dosage in 20 to 30 subjects with mild to moderate Alzheimer's dementia. BitNile holds significant ownership in Alzamend, owning approximately 10.4 million shares and rights to acquire additional shares.
Alzamend Neuro, Inc. (Nasdaq: ALZN) received a "Study May Proceed" letter from the FDA to initiate a Phase I/IIA clinical trial for ALZN002, an immunotherapy targeting mild to moderate dementia associated with Alzheimer’s. The trial aims to assess the safety and efficacy of the patient-specific treatment using autologous dendritic cells. Alzamend plans to dose the first patient in Q1 2023. Encouraging pre-clinical results show significant amyloid plaque reductions and no adverse side effects, supporting the IND application.
Alzamend Neuro (NASDAQ: ALZN) has commenced dosing in its Phase IIA study of AL001 for Alzheimer’s-related dementia.
The trial, initiated in May 2022, aims to assess the safety and tolerability of AL001 under multiple-dose conditions.
In response to FDA guidance, Alzamend is expanding the trial to include healthy adults, which may accelerate further testing for bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
AL001 presents a novel lithium delivery option, potentially offering therapeutic benefits with reduced toxicity compared to traditional lithium carbonate.
Alzamend Neuro, Inc. (Nasdaq: ALZN) has submitted an investigational new drug (IND) application to the FDA for ALZN002, an active immunotherapy targeting mild to moderate Alzheimer’s dementia. ALZN002 utilizes patients' dendritic cells to combat amyloid-beta proteins, aiming to offer a durable and safer treatment compared to passive immunization. The upcoming Phase I/IIA trial will assess safety and efficacy in 20-30 subjects. Preclinical studies demonstrated significant amyloid plaque reductions without adverse effects, supporting the IND submission and potential for advancing Alzheimer’s therapies.